Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias

Current Pharmaceutical Design

Volumn 18, Issue 23, 2012, Pages 3373-3388

  Robak, Tadeusz ^a,b   Robak, Pawel ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Regional Oncol Center   (Poland)

Author keywords

Cladribine; Clofarabine; Fludarabine; Forodesine; Hairy cell leukemia; Large granular lymphocyte leukemia; Nelarabine; Pentostatin; Prolymphocytic leukemia; Purine nucleoside analogs; T cell leukemia lymphoma

Indexed keywords

CLADRIBINE; CLOFARABINE; DNA; EPIRUBICIN; FLUDARABINE; FLUDARABINE 5' MONOPHOSPHATE; FORODESINE; NELARABINE; PENTOSTATIN; PREDNISOLONE; PRODRUG; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; UNCLASSIFIED DRUG;

ADD ON THERAPY; APOPTOSIS; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; DNA REPAIR; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; RABIES; REVIEW; T CELL LEUKEMIA; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PURINE NUCLEOSIDES;

EID: 84863514038     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212801227005     Document Type: Review

References (192)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H. WHO Classification, of Tumours of Haematopoietic and Lymphoid Tissues (4th ed.). International, Agency for Research on Cancer 2008.
2. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019-32.
3. Robak T. Emerging drugs for rarer chronic lymphoid leukemias. Expert Opin, Emerg Drugs 2008; 13: 95-118.
4. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006; 13: 3165-89.
5. Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 2009; 109: 2880-93.
6. Korycka A, Lech-Marańda E, Robak T. Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov 2008; 3: 123-36.
7. Robak T, Korycka A, Lech-Maranda E, Robak P. Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 2009; 14: 1183-226.
8. Pettit AR. Mechanism of action of purine analogues in chronic lymphocytic leukemia. Br. J. Haematol 2003; 121: 692-702.
9. Rodriquez CO, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 2002; 62: 3100-105.
10. Van den Neste E, Cardoen S, Offner F, Bontemps F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). Intern. J. Oncol. 2005; 27: 1113-24.
11. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005-37.
12. Mackey JR, Galmarini CM, Graham KA, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabinesensitive and-insensitive populations. Blood 2005; 105: 767-74.
13. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005-37.
14. Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with lowgrade non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J. Clin. Oncol 1999; 17: 1574-9.
15. Boogaerts MA. Oral fludarabine therapy in chronic lymphocytic leukemia- increased convenience. Hematology J 2004; 5: 31-7.
16. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952-6.
17. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737-43.
18. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest 1985; 75: 377-83.
19. Griffig J, Koob R, Blakley RL. Mechanism of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989; 49: 6923-8.
20. Carson DA, Carrera CJ, Wasson DB, Yamanaka H. Proogrammed cell death and adenine deoxynucleotide metabolism in humans lymphocytes. Adv. Enzyme Regul 1988, 27, 395-404.
21. Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytydine kinase and cytoplasmic 5'nucloetidase to the chemothrapeutic efficacy of 2-chlorodeoxyadenosine. Blood 1993; 81: 597-601.
22. Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. Nucleoside transporters in chronic lymphocytic leukemia. Leukemia 2004; 18: 385-93.
23. Genini D, Budihardjo I, Plunkett W, Wang X, Carrera CJ, Cottam HB, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J. Biol. Chem 2000; 275: 29-34.
24. Bosanquet AG, Sturm I, Wieder T, et al. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B-cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1035-44.
25. Albertioni F, Pettersson B, Reichelová V, Juliusson G, Liliemark J. Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solidphase extraction. The Drug Monit 1994; 16: 413-8.
26. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans. Cancer Res 1991; 51: 5570-2.
27. Robak T, Błasińska-Morawiec M, Krykowski E, et al. 2-hlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk. Lymphoma 1996; 22: 107-11.
28. Saven A, Cheung WK, Smith I et al. Pharmacokinetics study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. Clin. Oncol 1996; 14: 978-83.
29. Liliemark J, Albertioni F, Hassan M, Juliusson G. One the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol 1992; 10: 1514-8.
30. Brogden RN, Sorkin EM. Pentostatin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders. Drugs 1993; 4: 652-77.
31. Venner PM, Glazer RI, Blatt J, Sallan S, Rivera G, Holcenberg JS, et al. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia. Cancer Res 1981; 41: 4508-45.
32. Staubus AE, Weinrib AB, Malspeis L. An enzymatic kinetic method for the determination of 2'-deoxycoformycin in biological fluids. Biochem. Pharmacol 1984; 33: 1633-7.
33. Smyth JF, Paine RM, Jackman AL, et al. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin. Cancer. Chemother. Pharmacol. 1980; 5: 93-101.
34. Grever MR, Siaw MF, Jacob WF, et al. The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981; 57: 406-17.
35. Higman M, Vogelsang GB, Chen A. Pentostatin-pharmacology, munology, and clinical effects in graft-versus-host disease. Expert Opin Pharmacother. 2004; 5: 2605-13.
36. Robak T. New nucleoside analogs for patients with hematological malignancies. Expert Opin Investig Drugs 2011; 20: 343-59.
37. Lech-Maranda E, Korycka A, Robak T. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. Mini Rev Med Chem. 2009; 9: 805-12.
38. Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA. 3rd, Weitman S. Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat. Rev. Drug Discov., 2006; 5: 855-63.
39. Korycka A, Lech-Marańda E, Robak T. Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov 2008; 3: 123-36
40. Reichelova V, Liliemark J, Albertioni F. Liquid chromatographic study of acid stability of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, 2-chloro-2'-deoxy-adenosine and related analogues. J. Pharm. Biomed. Anal 1995; 13: 7114.
41. King KM, Damaraju VL, Vickers MF, et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol Pharmacol 2006; 69: 346-53.
42. Zhang Y, Secrist JA. 3rd; Ealick SE. The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation. Acta Crystallogr. D.Biol. Crystallogr 2006; 62: 133-9.
43. Lotfi K, Månsson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin. Cancer Res 1999; 5: 2438-44.
44. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103: 784-9.
45. Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin. Cancer Res. 2003; 9: 6335-42.
46. Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Rev Hematol 2010; 3: 15-22.
47. Roecker AM, Allison JC, Kisor DF. Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncol 2006; 2: 441-8.
48. Rodriguez CO, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 2002; 62: 3100-5.
49. Kisor DF. Nelarabine use in leukemias. Drugs Today 2006; 42: 455-65.
50. Ghandi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr. Opini. Oncol 2006; 18: 584-590.
51. Kisor DF, Plunkett W, Kurtzberg J, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J. Clin. Oncol 2000; 18: 995-1003.
52. Cohen MH, Johnson JR, Justice R, Pazdur R. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist 2008; 13: 709-14.
53. Korycka A, Błoński JZ, Robak T. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem 2007; 7: 976-83.
54. Evans GB, Furneaux RH, Lewandowicz A, Schramm VL, Tyler PC. Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J. Med. Chem 2003; 46: 5271-6.
55. Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006; 108: 2392-8.
56. Bantia S, Miller PJ, Parker CD et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)-a novel potent and orally active immunosuppressive agent. Intern. Immunopharmacol. 2001; 1: 1199-210.
57. Banthia S, Kilpatrick JM. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr. Oppinion Drug Discov. Develop 2004; 7: 243-7.
58. Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006; 108: 2392-8.
59. Balakrishnan K, Verma D, O'Brien S, et al. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 2010; 116: 886-92.
60. Lech-Maranda E, Robak E, Robak T. Novel systemic drugs for cutaneous T-cell lymphoma. Recent Pat Anticancer Drug Discov 2011; 6: 70-93.
61. Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol 2011; 29: 583-90.
62. Bernstein L, Newton P, Ross RK: Epidemiology of hairy cell leukemia: an update. Curr. Opin. Hematol 2003; 10: 258-66.
63. Fanta PT, Saven A. Hairy cell leukemia. Cancer Treat Res 2008; 142: 193-209.
64. Cannon T, Mobarek D, Wegge J, Tabbara IA. Hairy cell leukemia: current concepts. Cancer Invest 2008; 26: 860-5.
65. Goodman GR, Bethel KJ, Saven A.: Hairy cell leukemia: an update. Cur. Opin. Hematol 2003,10: 258-66.
66. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairycell leukemia. N Engl J Med 2011; 364: 2305-15.
67. Piro LD, Miller WE, Carrera CJ, Carson DA, Beutler E. Hairy cell leukemia. N Engl J Med 1987; 317: 901 (letter).
68. Saven A, Burian C, Kozioł JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-26.
69. Chadha P, Rademaker AW, Mendirata P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005; 106: 241-6.
70. Cheson BD, Sorensen JM, Vena DA. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group Protocol mechanism of the National Cancer Institute: a report of 979 ptients. J Clin Oncol 1998; 16: 3007-15.
71. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: Phenotype of hairy cell and lymphocyte subscts after treatment with 2-chlorodeoxyadenosie. Blood 1994; 83: 3672-81.
72. Robak T, Błasińska-Morawiec M, Krykowski E, et al. 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996; 22: 107-11.
73. Jehn U, Bartl R, Dietzfelbinger H, Haferlach T, Heinemann V. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 2004; 18: 1476-81.
74. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica 2004; 89: 309-13.
75. Zinzani PL, Pellegrini C, Stefoni V, et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. Cancer. 2010; 116: 4788-92.
76. Tallman MS, Zakarija A. Hairy cell leukemia survival and relapse: Long-term follow-up of purine analogs-based therapy and approach for relapsed disease. Transfus Apheresis Sci 2005; 32: 90-103.
77. Saven A, Burian C, Kozioł JA, Piro LD. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918-26.
78. Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years follow-up after 2-chlorodeoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma 1999; 35: 555-65.
79. Tallman MS, Hakkimian D, Variakojis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203-9.
80. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy cell leukemia with cladribine. Response toxicity and long-term followup. J Clin Oncol. 1997; 15: 1138-42.
81. Robak T, Błasińska-Morawiec M, Błoński J, et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol. 1999; 62: 49-56.
82. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006; 32: 365-76.
83. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009; 145: 733-40.
84. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs. A report of 219 patients with a median follow-up of 12.5 years. Cancer 2005; 104: 2442-8.
85. Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010; 115: 1893-6.
86. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003; 21: 891-6.
87. Lauria F, Boachia M, Marrotta G, Respadori D, Zinzani PL, Rondelli D. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia is effective and reduces infectious complications. Haematologica 1999; 84: 22-5.
88. Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood 2007; 109: 3672-5.
89. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13: 989-95.
90. von Rohr A, Schmitz SF, Tichelli A, et al. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Ann Oncol 2002; 13: 1641-9.
91. Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma 2011; 52: 75-8.
92. Ravandi F. Chemo-immunotherapy for hairy cell leukemia. Leuk Lymphoma. 2011; 52 Suppl 2: 72-4.
93. Spiers ASD, Parekh SJ, Bishop MB. Hairy cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin). J Clin Oncol. 1984; 2: 1336-42.
94. Spiers AS, Moore D, Casileth PA, et al. Remissions in hairy cell leukemia with pentostatin (2'-deoxycoformycin). N Engl J Med 1987; 316: 825-30.
95. Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7: 168-72.
96. Grever MR, Doan CA, Kraut EH. Pentostatin in the treatment of hairy cell leukemia. Best Pract Res Clin Haematol 2003; 16: 91-99.
97. Thaler J, Grunewald K, Gattinger C, et al. Long-term follow-up of patients with hairy cel leukemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration. Br J Haematol 1993; 84: 75-82.
98. Ribeiro P, Bouaffia F, Peaud PY, et al. Long-term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer 1999; 85: 65-71.
99. Rafel M, Cervantes F, Beltran JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 2000, 88: 352-7.
100. Johnston JB, Eisenhauer E, Wainman N, Corbett WE, Zaentz SD, Daeninck PJ. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol 2000; 27: 32-6.
101. Habermann TM, Andersen JW, Cassileth PA, Bennett JM, Oken MM. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukemia. Br J Haematol. 1992; 80: 466-71.
102. Guest JF, Smith H, Sladkevicius E, Jackson G. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. Clin Ther 2009; 2: 2398-415.
103. Maloisel F, Benboubker L, Gardembas M, et al. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia 2003; 17: 45-51.
104. Dearden CR, Matutes E, Hilditch BI, Swansbury GJ, Catovsky D. Long term follow-up patients with hairy cell leukemia after treatment with pentostatin or cladribine. Br J Haematol 1999; 106: 515-19.
105. Grever MR. Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas. Leuk Lymphoma 2011; 52: 25-8.
106. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an Intergroup study. J Clin Oncol 1995; 13: 974-82.
107. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000; 96: 2981-86.
108. Grever MR. Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas. Leuk Lymphoma 2011; 52 Suppl 2: 25-8.
109. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/ refractory hairy cell leukemia. Cancer 2007; 110: 2240-7.
110. Kantarjian H, Schachner J, Keating MJ. Fludarabine therapy in hairy cell leukemia. Cancer 1991; 67: 1291-3.
111. Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011; 37: 3-10.
112. Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003; 16: 41-56.
113. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural History and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001; 15: 184-6.
114. Blasińska-Morawiec M, Robak T, Krykowski E, Hellmann A, Urbańska-Ryń H. Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases. Leuk Lymphoma 1997; 25: 381-5.
115. Tetreault SA, Robbins BA, Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk Lymphoma 1999; 35: 347-54.
116. Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica 2002; 87: 107-8.
117. Machii T, Chou T, Suzuki M, et al. Cladribine Study Group. Phase II clinical study of cladribine in the treatment of hairy cell leukemia. Int J Hematol 2005; 82: 230-5.
118. Miyazaki M, Taguchi A, Sakuragi S, Mitani N, Matsuda K, Shinohara K. Hairy cell leukemia, Japanese variant, successfully treated with cladribine. Rinsho Ketsueki 2004; 45: 405-7.
119. Imamura T, Ohtsuka E, Ogata M, et al. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia-Japanese variant. Int J Hematol 2004; 80: 432-4.
120. Kitani T, Machii T, Inoue R, Kanakura Y. Hairy cell leukemia: a report of 10 cases in Japan and characterization of anti-hairy cell sera. Jpn J Clin Oncol.1983; 13: 497-509.
121. Lefrère F, Hermine O, François S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000; 40: 113-7.
122. Robak T. Management of hairy cell leukemia variant. Leuk Lymphoma 2011; 52: 53-6.
123. Polliack A. Hairy cell leukemia and allied chronic lymphoid leukemias: current knowledge and new therapeutic options. Leuk Lymphoma 1997; 26: 41-51.
124. Sainati L, Matutes E, Mulligan S, et al. variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 1990; 76: 157-62.
125. Catovsky D, Matutes E, Talavera JG, et al. Long-term results with 2'-deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 1994; 14: 108-13.
126. Dunphy CH, and Petrusk PJ. Atypical prolymphocytic variant of hairy cell leukemia: Case report and review of the literature. Am J Hematol 1996; 53: 121-5.
127. Ng JP, Nolan B, Chan-Lam D, Coup AJ, McKenna D. Successful treatment of aplastic variant of hairy-cell leukaemia with deoxycoformycin. Hematology 2002; 7: 259-62.
128. Nagai T, Izumi T, Noborio K, et al. Successful treatment of hairy cell leukemia prolymphocytic variant with 2'-deoxycoformycin. Rinsho Ketsueki 2002; 43: 583-5.
129. Ribeiro P, Bouaffia F, Peaud PY, et al. Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer. 1999; 85: 65-71.
130. Dearden CE. T-cell prolymphocytic leukemia. Clin Lymphoma Myeloma. 2009; 9: S239-43.
131. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology. 2000; 36: 69-86.
132. Khot A, Dearden C. T-cell prolymphocytic leukemia. Expert Rev Anticancer Ther 2009; 9: 365-71.
133. Dearden CE. T-cell prolymphocytic leukemia. Clin Lymphoma Myeloma. 2009; 9: S239-43.
134. Dungarwalla M, Matutes E, Dearden CE. Prolymphocytic leukaemia of B-and T-cell subtype: a state-of-the-art paper. Eur J Haematol 2008; 80: 469-76.
135. Robak T, Robak P. Current treatment options in prolymphocytic leukemia. Med Sci Monit 2007; 13: 69-80.
136. Ho AD, Hensel M. Pentostatin and purine analogs for indolent lymphoid malignancies. Future Oncol 2006; 2: 169-83.
137. Lorand-Metze I, Oliveira GB, Aranha FJ. Treatment of prolymphocytic leukemia with cladribine. Ann Hematol 1998; 76: 85-6.
138. Doorduijn JK, Michiels JJ. Effectiveness of fludarabine in endstage prolymphocytic leukemia. Leukemia 1994; 8: 1439.
139. Marlton P, McCarthy C, Taylor K. Fludarabine-induced cytogenetic remission in prolymphocytic leukemia. Am J Hematol 1992; 40: 71-2.
140. Jeong KH, Lew BL, Sim WY. Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis. Acta Derm Venereol 2009; 89: 509-12.
141. Sporn JR. Sustained response of refractory prolymphocytic leukemia to fludarabine. Acta Haematol 1991; 85: 209-11.
142. Krishnan B, Else M, Tjonnfjord GE, et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol 2010; 149: 907-10.
143. Kalaycio ME, Kukreja M, Woolfrey AE, et al. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant 2010; 16: 543-7.
144. Kantarjian, HM, Childs C, O'Brien S, et al. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the mphocytoid variant of chronic lymphocytic leukemia. Am J Med 1991; 90: 223-8.
145. Doorduijn JK, Michiels JJ. Effectiveness of fludarabine in endstage prolymphocytic leukemia. Leukemia 1994; 8: 1439.
146. Naranjo TA, Matutes E, Martinez JJ, et al. Prolymphocytic leukaemia and Hodgkin's lymphoma. Eur J Haematol. 2002; 69: 182-4.
147. Andrieu V, Encaoua R, Carbon C, Couvelard A, Grange MJ. Leukemic pleural effusion in B-cell prolymphocytic leukemia. Hematol Cell Ther 1998; 40: 275-8.
148. Whelan JS, Davis CL, Rule S, et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 1991; 64: 120-3.
149. Cannon LM, Spilove L, Rhodes R, Garfinkel H, Pezzimenti J. Acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia. Conn Med 1993; 57: 651-4.
150. Chow KU, Kim SZ, von Neuhoff N, et al. Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab (FER) in the treatment of chronic lymphocytic leukaemia and prolymphocytic leukaemia. Eur J Haematol 2011; 87: 426-33.
151. Tempescul A, Feuerbach J, Lanotto JC, et al. A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. Ann Hematol 2009; 88: 85-8.
152. Telek B, Batár P, Rejto L, Udvardy M. Successful treatment of Bcell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol. Orv Hetil 2010; 151: 1261-3.
153. Montillo M, Tedeschi A, O'Brien S, et al. Phase II study of cladribine and cyclophosphmide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003; 97: 114-20.
154. Saven A, Lee J, Schlutz M, Jacobs A, Ellison D, Longmire R. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol. 1997; 15: 37-43.
155. Shvidel L, Shtalrid M, Bassous I, Klepfish A, Vorst E, Berrebi A. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 1999; 33: 169-79.
156. Delannoy A. 2-Chloro-2'-deoxyadenosine: clinical applications in hematology. Blood Rev 1996; 10: 148-66.
157. Palomera L, Domingo JM, Agullo JA, Soledad Romero M. Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine. J Clin Oncol 1995; 13: 1284-5.
158. Lorand-Metze I, Oliveira GB, Aranha FJ. Treatment of prolymphocytic leukemia with cladribine. Ann Hematol 1998; 76: 85-6.
159. el'Agnaf MR, Ennis KE, Morris TC, Robertson JH, Markey G, Alexander HD. Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukemia. Br J Haematol 1986; 63: 93-104.
160. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol. 1994; 12: 2588-93.
161. Döhner H, Ho AD, Thaler J. et al. Pentostatin in prolymphocytic leukemia phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J Natl Cancer Inst 1993; 85: 658-62.
162. Pagano L, Ortu-La Barbera E, Voso MT, et al. Salvage chemotherapy with pentostatin in prolymphocytic leukemia. Haematologica 1994; 79: 542-5.
163. Furman RR, Gore L, Ravandi F, Hoelzer D.: Forodesine IV (Bex-1777) is clinically active in relapsed/refractory T-cell leukemia: results of a phase II study. (Interim report) Blood, 2006,108(Suppl 1): 524a (Abstract 1851).
164. Balakrishnan K, Verma D, O'Brien S, et al. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 2010; 116: 886-92.
165. Gandhi V, Tam C, O'Brien S, et al. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol 2008; 26: 1098-105.
166. Alekshun TJ, Sokol L. Diseases of large granular lymphocytes. Cancer Control 2007; 14: 141-50.
167. Sokol L, Loughran TP.Ir: Large granular lymphocyte leukemia: Oncologist, 2006; 11: 263-73.
168. Fortune AF, Kelly K, Sargent J, et al. Large granular lymphocyte leukemia: natural history and response to treatment. Leuk Lymphoma 2010; 51: 839-45.
169. Watters RJ, Liu X, Loughran TP, Jr. T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias Leuk Lymphoma, 2011; 52: 2217-25.
170. Prochorec-Sobieszek M. Advances in diagnosis and treatment of large granular lymphocyte syndrome. Curr Opin Hematol 2011; 18: 55-60.
171. Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117: 2764-74.
172. Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol 2011; 152: 273-83.
173. Witzig TE, Weitz JJ, Lundberg JH, Tefferi A. Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. Leuk Lymphoma 1994; 14: 137-9.
174. Sternberg A, Eagleton H, Pillai N, et al. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. Br J Haematol. 2003; 120: 699-701.
175. Aribi A, Huh Y, Keating M, et al. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res 2007; 31: 939-45.
176. Ma SY, Au WY, Chim CS, et al. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B-and T-cell lymphoid malignancies in Chinese patients. Br J Haematol 2004; 124: 754-61.
177. Tse E, Chan JC, Pang A, et al. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. Leukemia 2007; 21: 2225-6.
178. O'Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994; 84: 733-8.
179. Edelman MJ, O'Donnell RT, Meadows I. Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. Am J Hematol. 1997; 54: 329-31.
180. Dincol G, Diz-Kuçukkaya R, Bicakci E. T-cell large granular lymphocytic leukaemia: successful response to 2-deoxycoformycin. Neth J Med 2008; 66: 85-7.
181. Yoe J, Gause BL, Curti BD, et al. Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin. Am J Haematol 1998; 57: 253-7.
182. Tsirigotis P, Venetis E, Kapsimali V, et al. 2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia. Leuk Res 2003; 27: 865-7.
183. Yasunaga J, Matsuoku M. Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control 2007; 14: 133-40.
184. Tanosaki R, Tobinai K. Adult T-cell leukemia-lymphoma: current treatment, strategies and novel immunological approaches. Expert Rev Hematol 2010; 3: 743-53.
185. Foucar, K. Mature T-cell leukemia including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma and Sezary syndrome. Am. J. Clin. Pathol., 2007; 127: 496-510.
186. Yamada Y, Tomonoga M: The current status of therapy for adult Tcell leukemia-lymphoma in Japan. Leuk. Lymphoma 2003, 44, 611-8.
187. Okamura J, Uike N, Utsunomiya A, Tanosaki R. Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma. Int J Hematol 2007; 86: 118-25.
188. Nishioka C, Ikezoe T, Yang J, Koeffler HP, Taguchi H. Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappaB signal pathway. Leukemia 2007; 21: 1044-9.
189. Uike N, Choi I, Tokoro A, Goto T, Yufu Y, Kozuru M, Tobinai K. Adult T-cell leukemia-lymphoma successfully treated with 2-chlorodeoxyadenosine. Intern Med 1998; 37: 411-3.
190. Tobinai K, Uike N, Saburi Y, et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int J Hematol 2003; 77: 512-7.
191. Ravandi F, Faderl S. Complete response in a patient with adult Tcell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res 2006, 30: 103-5.
192. Tsukasaki K, Tobinai K, Shimoyama M, et al. Deoxycoformycincontaining combination chemotherapy for adult T-cell leukemialymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 2003; 77: 164-70.